Inspire Veterinary Partners (IVP) issues 9.45M shares for financing consulting

Rhea-AI Filing Summary

Inspire Veterinary Partners, Inc. entered into a new Consulting Agreement with 622 Capital LLC on December 12, 2025. Under this agreement, the consultant will provide business development services focused on business financing opportunities.

As consideration for these services, Inspire Veterinary Partners agreed to issue an aggregate of 9,450,000 shares of its Class A common stock. Of this total, 3,300,000 shares were issued upon execution of the agreement, and an additional 6,150,000 shares are issuable within five business days after execution. These shares are being issued under the company’s 2022 Equity Incentive Plan and are registered on a Form S-8. The agreement also includes customary representations, covenants, indemnification, and confidentiality provisions and remains in effect until terminated according to its terms.

Insights

Equity Compensation & Governance Analyst

Inspire Veterinary grants 9.45M shares for financing-focused consulting services.

Inspire Veterinary Partners has committed a substantial equity package of 9,450,000 Class A common shares to 622 Capital LLC as compensation for business development services centered on financing opportunities. The structure splits the grant into 3,300,000 shares issued at signing and 6,150,000 shares to be issued within five business days after execution, which concentrates compensation in a short time frame rather than over a long vesting period.

The shares are issued under the company’s 2022 Equity Incentive Plan and are registered on a Form S‑8, indicating they rely on an existing equity compensation framework rather than a new capital markets transaction. The agreement includes standard representations, covenants, indemnification, and confidentiality terms and continues until terminated in line with its provisions. Future company disclosures may provide additional context on how these consulting services affect financing outcomes and overall capital structure.

8-K Event Classification

Item 1.01 — Entry into a Material Definitive Agreement

1 item

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Understanding 8-K Material Events →

false 0001939365 0001939365 2025-12-12 2025-12-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 12, 2025

INSPIRE VETERINARY PARTNERS, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-41792		85-4359258
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification No.)

780 Lynnhaven Parkway, Suite 400 Virginia Beach, VA		23452
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (757) 734-5464

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001		IVP		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On December 12, 2025, Inspire Veterinary Partners, Inc. (the “Company”) entered into a Consulting Agreement (the “Consulting Agreement”) with 622 Capital LLC, a single member limited liability company (the “Consultant”), pursuant to which the Consultant will provide the Company with business development services related to business financing opportunities.

In consideration for the services to be provided under the Consulting Agreement, the Company agreed to issue the Consultant an aggregate of 9,450,000 shares of the Company’s Class A common stock, par value $0.0001 per share (the “Shares”) issuable as follows: 3,300,000 Shares were issued upon execution of the Consulting Agreement and 6,150,000 Shares are issuable within five business days after the execution of the Consulting Agreement. The Shares are being issued pursuant to the Company’s 2022 Equity Incentive Plan and are registered on the Company’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission. The Consulting Agreement contains customary representations, covenants, and indemnification and confidentiality provisions and will remain in effect until terminated in accordance with its terms.

The foregoing description of the Consulting Agreement is qualified in its entirety by reference to the Consulting Agreement, a copy of which is filed as an exhibit to this Current Report on Form 8-K and is incorporated herein by reference.

Item. 9.01. Financial Statements and Exhibits

Exhibit No.		Description
10.1		Consulting Agreement, dated December 12, 2025, between Inspire Veterinary Partners, Inc. and 622 Capital LLC.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 17, 2025	INSPIRE VETERINARY PARTNERS, INC.
	By:	/s/ Kimball Carr
	Name:	Kimball Carr
	Title:	President and Chief Executive Officer

2

FAQ

What agreement did Inspire Veterinary Partners (IVP) enter into on December 12, 2025?

Inspire Veterinary Partners entered into a Consulting Agreement with 622 Capital LLC, under which the consultant will provide business development services related to business financing opportunities.

How many shares is Inspire Veterinary Partners (IVP) issuing to 622 Capital LLC?

The company agreed to issue an aggregate of 9,450,000 shares of Class A common stock to 622 Capital LLC as consideration for the consulting services.

How are the 9,450,000 Inspire Veterinary Partners shares structured under the consulting deal?

Of the 9,450,000 shares, 3,300,000 shares were issued upon execution of the Consulting Agreement, and 6,150,000 shares are issuable within five business days after execution.

Under what plan are the Inspire Veterinary Partners (IVP) shares to the consultant being issued?

The shares issued to 622 Capital LLC are being issued pursuant to Inspire Veterinary Partners’ 2022 Equity Incentive Plan and are registered on a Form S-8 registration statement.

What services will 622 Capital LLC provide to Inspire Veterinary Partners (IVP)?

622 Capital LLC will provide business development services for Inspire Veterinary Partners, specifically related to business financing opportunities.

Does the Consulting Agreement between Inspire Veterinary Partners and 622 Capital LLC include standard legal protections?

Yes. The Consulting Agreement includes customary representations, covenants, and indemnification and confidentiality provisions and remains in effect until terminated in accordance with its terms.